中生北控生物科技(08247)发布2023年度业绩，股东应占亏损1164.8万元
中生北控生物科技(08247)发布截至2023年12月31日止年度业绩，营业收入达约2.891亿元(人民币，下同)，同比减少约22.5%;母公司拥有人应占亏损1164.8万元，上年同期溢利810.6万元;每股基本亏损0.080元。
于本年度内，营业收入同比减少约22.5%，主要由于受国内外公共卫生防控政策变化的影响导致市场需求下降，以及受行业集中采购的影响导致产品价格下跌。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.